Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
Shanshan HuShengying GuChendong QiShuowen WangFengdan QianChenyang ShiGuorong FanPublished in: Diabetes, obesity & metabolism (2022)
After its addition to the National Medical Insurance System in China, SEMA is expected to be a cost-effective choice compared with DULA for patients with type 2 diabetes with inadequately controlled from the cost-utility analysis. However, there is still scope to reduce the annual cost of SEMA further.